Join
Live feed
·
PRReleasevia Quantisnow
GlycoMimetics Inc. logo

GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

ByQuantisnow·Wall Street's wire, on your screen.
GLYC· GlycoMimetics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track GLYC (GlycoMimetics Inc.) and more on Quantisnow.